Alumis' stock dropped 56.58% after its Phase II lupus drug trial failed to meet main goals, causing a significant market reaction. However, positive results in a subgroup of lupus patients with a high interferon gene signature offer a potential path for future development. The company remains on track to submit a New Drug Application for its psoriasis treatment in Q4 2026, which supports some of its future value. An analyst lowered the price target from $35 to $27 amid these developments, with the stock trading at $9.47 per share at the time.
Alumis Inc. shares dropped 56.76% after its Phase 2b trial for a lupus drug failed to meet key goals, though some patient groups showed promise. Enovis Corporation shares fell 16.51% following its announcement to acquire eCential Robotics for €155 mi...
SPAC stocks like Rising Dragon Acquisition surged nearly 47% amid volatility, while biotech firm bioAffinity Technologies jumped 44% after a reverse stock split. Renewable energy company Fervo Energy gained 28% following a major geothermal power deal...
Enovis has lowered its price target to $27 from $30 following its binding offer to acquire eCential Robotics for €155 million. This acquisition aims to strengthen Enovis's position in surgical robotics and enhance its ASTRA technology ecosystem. Desp...
Citigroup reaffirmed its Buy rating on NIO but lowered the price target from $8.20 to $7.10 due to NIO's second-quarter deliveries and revenue missing company guidance and a third-quarter outlook below Wall Street estimates. Despite a 49.4% year-over...
Yum! Brands recently sold its Pizza Hut division and CEO Christopher Lee Turner sold shares amid legal scrutiny. The company is under investigation by Pomerantz LLP for possible securities fraud following a food safety crisis linked to a cyclosporias...
